Method for producing osteoclast differentiation-inhibitory extract and method for separating osteoclast differentiation-inhibitory extract

The extraction and membrane separation of dried sardines produce an osteoclast differentiation-inhibiting extract, addressing the lack of clarity in existing methods and providing a safe, simple solution for bone strengthening.

JP2024159322APending Publication Date: 2024-11-08NAT UNIV CORP EHIME UNIV +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023075245
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-04-28
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing methods for promoting bone strengthening, such as those using dried sardines, lack clarity on which foods to consume and do not provide a safe and simple method for producing an osteoclast differentiation-inhibiting extract.

Method used

A method involving the extraction of dried sardines with liquid water followed by separation of components using a separation membrane, specifically dialysis or ultrafiltration membranes, to remove components above 14 kDa or 10 kDa, resulting in an osteoclast differentiation-inhibiting extract.

Benefits of technology

A safe and simple method is provided for producing an osteoclast differentiation-inhibiting extract using daily foods, effectively inhibiting osteoclast differentiation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024159322000001_ABST
    Figure 2024159322000001_ABST
Patent Text Reader

Abstract

To provide a safe and simple method for producing osteoclast differentiation-inhibitory extract using daily-consumed foods.SOLUTION: A method for producing osteoclast differentiation-inhibitory extract includes the steps of: extracting dried small sardines with liquid water; and separating components contained in the extracted water through a separation membrane. The step for separating the components contained in the extracted water through the separation membrane is performed by dialysis and ultrafiltration. It is preferable that components with a molecular weight exceeding 10 kDa are removed from the extracted water.SELECTED DRAWING: Figure 8
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for producing an osteoclast differentiation-inhibiting extract and a method for separating an osteoclast differentiation-inhibiting extract. [Background technology]

[0002] The bones of humans and animals are not simply inorganic structures; they undergo a metabolic process in which cells induce the replacement of old bone components with new bone components, and they change every day. Specifically, old bone is absorbed and destroyed by osteoclasts, while new bone is formed in the destroyed area by osteoblasts. Bone metabolism is possible by constantly regulating bone absorption and regeneration through cell induction. This type of bone metabolism is usually called bone remodeling.

[0003] Research into the mechanism of osteoclast function is also progressing, and it is known that RANKL (receptor activator of nuclear factor-kappa B ligand, a type of protein) functions as a differentiation-inducing factor for osteoclast precursor cells. Fusion of osteoclast precursor cells with RANKL promotes osteoclast differentiation.

[0004] Against the background of the promotion of differentiation of osteoclast precursor cells, for example, changes in physical condition due to aging in elderly people may disrupt the coordinated relationship between osteoclasts and osteoblasts in their activities on bone. Specifically, even if osteoclast activity remains the same, when osteoblast activity decreases, bone components are absorbed by osteoclasts over time, leading to a decrease in bone density. If bone density decreases and bones become osteoporosis, this can have an impact on daily life, such as making bones more susceptible to fracture. Even if a new drug that inhibits osteoclast differentiation were developed, there is concern that because reactions in the body are intricately interrelated, malfunctions in other reactions in the body may occur, resulting in side effects.

[0005] There is prior art that addresses this problem of reduced bone density. For example, a method for producing an extract for promoting bone strengthening that contains at least one selected from the group consisting of maltobionic acid represented by the general formula 4-O-α-D-glucopyranosyl-D-gluconic acid, its salts and its lactones, and also contains a calcium component, has been proposed as prior art (Patent Document 1). According to this prior art, dried sardines are cited as an example of a calcium component. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] JP 2016-117752 A Summary of the Invention [Problem to be solved by the invention]

[0007] However, in the above-mentioned prior art, many foods other than dried sardines are listed as calcium sources, making it difficult to know which foods should be ingested to further promote bone strengthening. Furthermore, the above-mentioned prior art focuses on the supply of calcium components to strengthen bones when it comes to dried sardines, and does not disclose anything about dried sardines other than the source of the calcium components.

[0008] An object of the present invention is to provide a safe and simple method for producing an osteoclast differentiation-inhibiting extract using foods that are ingested on a daily basis, and a method for isolating the osteoclast differentiation-inhibiting extract. [Means for solving the problem]

[0009] In order to solve the above problems, the inventors conducted intensive research and discovered that a method for producing an osteoclast differentiation-inhibiting extract, which includes a step of extracting dried sardines with liquid water and a step of separating the components contained in the extracted water using a separation membrane, is suitable for the objectives of the present invention, and thus completed the present invention.

[0010] That is, the present invention provides: [1] A step of extracting dried sardines with liquid water, and a step of separating components contained in the extracted water using a separation membrane; The present invention provides a method for producing an osteoclast differentiation-inhibiting extract, which is characterized by comprising:

[0011] Another aspect of the present invention is [2] A method for extracting dried sardines with liquid water, a method for separating the extracted water from a suspension of the dried sardines and liquid water, and a method for separating components contained in the extracted water using a separation membrane; The step of separating the components contained in the extracted water using a separation membrane is a dialysis step, and the separation membrane is a dialysis membrane; The present invention provides a method for producing the osteoclast differentiation-inhibiting extract described in [1] above, wherein the step of separating the components contained in the extracted water using a separation membrane includes a step of removing components having a molecular weight exceeding 14 kDa from the extracted water.

[0012] Another aspect of the present invention is [3] A method for extracting dried sardines with liquid water, a method for separating the extracted water from a suspension of the dried sardines and liquid water, and a method for separating components contained in the extracted water using a separation membrane; The step of separating components contained in the extracted water using a separation membrane is an ultrafiltration step, and the separation membrane is an ultrafiltration membrane; The present invention provides a method for producing the osteoclast differentiation-inhibiting extract described in [1] above, wherein the step of separating the components contained in the extracted water using a separation membrane includes a step of removing components having a molecular weight exceeding 10 kDa from the extracted water.

[0013] The present invention also provides [4] A step of extracting dried sardines with liquid water, and a step of separating components contained in the extracted water using a separation membrane; The present invention provides a method for isolating an osteoclast differentiation-inhibiting extract, which is characterized by containing:

[0014] Another aspect of the present invention is [5] A method for extracting dried sardines with liquid water, separating the extracted water from a suspension of the dried sardines and liquid water, and separating components contained in the extracted water using a separation membrane; The step of separating the components contained in the extracted water using a separation membrane is a dialysis step, and the separation membrane is a dialysis membrane; The present invention provides a method for separating the osteoclast differentiation-inhibiting extract described in [4] above, wherein the step of separating the components contained in the extracted water using a separation membrane includes a step of removing components having a molecular weight exceeding 14 kDa from the extracted water.

[0015] [6] A method for extracting dried sardines with liquid water, separating the extracted water from a suspension of the dried sardines and liquid water, and separating components contained in the extracted water using a separation membrane; The step of separating components contained in the extracted water using a separation membrane is an ultrafiltration step, and the separation membrane is an ultrafiltration membrane; The present invention provides a method for separating the osteoclast differentiation-inhibiting extract described in [5] above, wherein the step of separating components contained in the extracted water using a separation membrane includes a step of removing components having a molecular weight exceeding 10 kDa from the extracted water. Effect of the Invention

[0016] According to the method for producing an osteoclast differentiation-inhibiting extract of the present invention, it is possible to provide a safe and simple osteoclast differentiation-inhibiting extract and a method for isolating the osteoclast differentiation-inhibiting extract using foods that are ingested on a daily basis. [Brief description of the drawings]

[0017] [Figure 1] FIG. 1 is a graph showing the results of a cytotoxicity evaluation test using Sample 1. [Diagram 2] FIG. 2 is a graph showing the inhibitory effect on osteoclast differentiation, using the expression of tartrate-resistant acid phosphatase (TRAP), an osteoclast marker enzyme, as an indicator. [Diagram 3] FIG. 3 is a graph showing the inhibitory effect on osteoclast differentiation when dried powder of boiled and dried sardines is extracted with boiled water and cold water, respectively. [Figure 4] FIG. 4 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells before induction of differentiation. [Diagram 5] FIG. 5 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells after stimulation with a differentiation inducer for 5 days. [Figure 6] FIG. 6 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells after extraction of dried sardine powder with water at 8° C. and stimulation with a differentiation inducer for five days. [Figure 7] FIG. 7 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells after extraction with dried sardine powder in boiling water at 100° C. for 10 minutes and then stimulation with a differentiation inducer for 5 days. [Figure 8] FIG. 8 is a graph showing the inhibitory effect on osteoclast differentiation when a dialysis membrane with a molecular weight cutoff of 14 kDa was used. [Figure 9] FIG. 9 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells before induction of differentiation. [Figure 10] FIG. 10 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells after stimulation with a differentiation inducer for 5 days. [Figure 11] FIG. 11 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells after stimulation with a differentiation inducer for 5 days in the case of Example 1, without dialysis. [Figure 12] FIG. 12 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells after dialysis in Example 1 and stimulation with a differentiation inducer for 5 days. [Figure 13] FIG. 13 is a graph showing the inhibitory effect on osteoclast differentiation when an ultrafiltration membrane with an average molecular weight cutoff of 10 kDa was used. [Figure 14] FIG. 14 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells before induction of differentiation. [Figure 15]FIG. 15 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells after stimulation with a differentiation inducer for 5 days. [Figure 16] FIG. 16 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells after stimulation with a differentiation inducer for 5 days in the case of Example 2, without ultrafiltration. [Figure 17] FIG. 17 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells after stimulation with a differentiation inducer for 5 days using the components concentrated by ultrafiltration in Example 2. [Figure 18] FIG. 18 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells after stimulation with a differentiation inducer for 5 days in the fraction from which high molecular weight components were removed by ultrafiltration in the case of Example 2. [Figure 19] FIG. 19 is a graph showing the relationship between the timing of addition and the effect of using a water extract of dried sardines. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] First, the boiled and dried fish used in the present invention will be described. There is no particular limitation on the raw material for the dried sardines used in the present invention, but examples include one or more types of raw fish such as anchovy, Japanese sardine, round herring, silver-stripe round herring, horse mackerel, mackerel, and flying fish. The method for producing dried sardines using the raw fish may be a known method. For example, the raw fish may be dried as is, or the processed fish obtained after steps such as cutting and removing the head and separating and removing the innards may be dried. The raw or processed fish may also be heated before drying. The heating method may be one or more of the following: heating with hot water, heating in a heating oven, heating using non-contact means such as microwaves or infrared rays, and heating with steam.

[0019] There is no limitation on the method for drying raw fish or processed fish, but examples include one or more of the following: drying in the sun, circulating warm air in a heating oven, reducing pressure while heating in a heating oven, heating by non-contact means such as microwaves or infrared rays, and circulating internal air while heating by non-contact means such as microwaves or infrared rays. In addition, in order to prevent deterioration of the dried sardines, gases other than air, such as nitrogen and carbon dioxide, can also be used in the manufacturing process of dried sardines.

[0020] When producing dried sardines, additives such as salt and umami seasonings can be appropriately selected and added.

[0021] The dried sardines used in the present invention can be appropriately selected from commercially available products, but for example, it is preferable to use sardines such as anchovy, Japanese pilchard, and round herring as the raw fish, and anchovy is more preferable.

[0022] The dried sardines used in the present invention preferably have an energy content per 50 g in the range of 100 to 200 kcal, and more preferably have a protein content in the range of 20 to 40 g.

[0023] The dried sardines used in the present invention are preferably crushed before use in order to increase the extraction efficiency.

[0024] Next, the process of extracting dried sardines with liquid water used in the present invention will be described. The reason why the expression "liquid water" is used in the process of extracting the dried sardines with liquid water is that the upper limit of the temperature of the water used for extraction is not limited to 100°C under normal pressure, but temperatures exceeding 100°C under pressure can also be used. The temperature at which the boiled and dried fish is extracted with liquid water is preferably within the range of 5 to 125°C. The extraction time is preferably in the range of 5 to 30 minutes.

[0025] The water used in the present invention is not limited to pure water, and may be, for example, one or more of tap water, industrial water, seawater, etc. If necessary, liquids other than water, such as ethanol, and additives such as salt and seasonings, may also be used in combination.

[0026] When extracting dried sardines with liquid water, it is preferable to bring the water and dried sardines into contact with each other and then stir them together. As a stirring method, for example, one or more of a method of rotating the mixture with a stirring blade, a method of rotating the container itself, a method of blowing steam into the container, and the like can be adopted.

[0027] Next, the process of separating the extract water from the suspension of dried sardines and liquid water will be described. Methods for separating the extract water from a suspension of dried sardines and liquid water can include, for example, one or more of the following: leaving the suspension to stand and separating the supernatant liquid; rotating the suspension and separating the liquid by centrifugation; and filtering using a filtering member such as a filter cloth or filter paper. By the above method, the extraction water can be separated.

[0028] Next, the step of separating the components contained in the extract water using a separation membrane will be described. The step of separating the components contained in the extract water using a separation membrane can specifically include at least one of a dialysis step, an ultrafiltration step, and the like. The separation membrane used in the present invention may be, for example, at least one of a dialysis membrane and an ultrafiltration membrane. For example, the extract may be contacted with water via a separation membrane. Examples of the method for contacting the extract with water include a method in which the extract is wrapped in a separation membrane and immersed in water, a method in which water is wrapped in a separation membrane and immersed in the extract, a method in which the extract is placed in one side of a container partitioned by a separation membrane and water is placed in the other side and the two are brought into contact via the separation membrane, a method in which a separation membrane is formed into a cylindrical shape and the outside is immersed in water while the extract is moved inside, etc. One or more of these methods can be appropriately selected and used.

[0029] In the dialysis step, for example, dialysis is performed for 3 to 5 hours against an external solution (water) in an amount 500 to 2000 times the amount of liquid inside the separation membrane to be dialyzed. In addition, the external solution is replaced with an equal amount of the external solution and dialyzed for an additional 6 to 24 hours, preferably 8 to 14 hours. The dialysis step is preferably carried out in a refrigerator at 4 to 6°C. When the dialysis step is carried out at normal pressure, it is preferable to use a dialysis membrane as the separation membrane.

[0030] In the step of separating the components contained in the extract water using a separation membrane, for example, in the case of the above-mentioned dialysis step, pressure can be applied to the extract liquid as necessary. The pressure to be applied can be appropriately set taking into consideration the pressure resistance and separation efficiency of the separation membrane. Processes carried out under pressure are commonly called ultrafiltration processes. The pressure when carrying out ultrafiltration is appropriately set depending on the device used and the amount of sample, but is, for example, in the range of 0.1 to 1 MPa. The separation membrane used for ultrafiltration can be appropriately selected from commercially available ultrafiltration membranes, for example.

[0031] In the present invention, the step of separating the components contained in the extract water using a separation membrane preferably includes a step of removing components having a molecular weight of more than 14 kDa from the extract water. The material of the separation membrane used in the present invention is preferably one that can remove components having a molecular weight exceeding 14 kDa from the extraction water, and commercially available materials can be appropriately selected and used. Furthermore, the separation membrane used in the present invention is only required to have the ability to remove components having a molecular weight of more than 14 kDa from the extraction water, and does not necessarily have to be capable of removing all components having a molecular weight of more than 14 kDa from the extraction water. The separation membrane used in the present invention is preferably capable of removing 50% or more of components having a molecular weight of more than 14 kDa, and more preferably capable of removing 80% or more.

[0032] In the present invention, the step of separating the components contained in the extract water using a separation membrane preferably includes a step of removing components having a molecular weight of more than 10 kDa from the extract water. The material of the separation membrane used in the present invention is preferably one that can remove components having a molecular weight of more than 10 kDa from the extract water, and commercially available materials can be appropriately selected and used. In addition, the separation membrane used in the present invention is only required to have the ability to remove components having a molecular weight of more than 10 kDa from the extract water, and does not necessarily have to be able to remove all components having a molecular weight of more than 10 kDa from the extract water. The separation membrane used in the present invention is preferably one capable of removing 50% or more of components having a molecular weight of more than 10 kDa, and more preferably one capable of removing 80% or more.

[0033] In the present invention, the step of removing components having a molecular weight of more than 10 kDa from the extraction water is preferably carried out by applying pressure. More preferably, the step of removing components having a molecular weight of more than 10 kDa from the extraction water is an ultrafiltration step. The separation membrane used in the ultrafiltration step is preferably an ultrafiltration membrane.

[0034] Next, the step of evaporating water from the separated extracted water will be described. Examples of methods for evaporating water after the step of separating components contained in the extract water using a separation membrane include a method of heating or boiling the separated extract water to evaporate water, a method of heating the separated extract water under reduced pressure, a method of putting the separated extract water into a container and heating it in a heating oven while circulating the air inside, a method of putting the separated extract water into a container and drying it in the sun, a method of freeze-drying the separated extract water, etc. One or more of these methods can be appropriately selected and used. The method for evaporating water from the separated extract preferably includes freeze-drying, in which the separated extract is frozen, the frozen separated extract is placed in an apparatus, and the pressure inside the apparatus is reduced. The temperature at which the freeze-drying is carried out is preferably in the range of -196°C to 0°C. The pressure is preferably in the range of 5 Torr to 700 Torr, and the freeze-drying time is preferably in the range of 30 minutes to 24 hours.

[0035] By the above steps, an osteoclast differentiation-inhibiting extract can be produced, and the osteoclast differentiation-inhibiting extract can be separated from the dried sardines.

[0036] The present invention will now be described with reference to examples, but the present invention is not limited to the contents of the following examples.

[0037] [Preliminary experiment 1] 2.0 g of commercially available dried sardine powder (Marutomo) was suspended in distilled water to a total concentration of 0.1 g / mL. The temperature was then kept at 8°C and the mixture was stirred for 24 hours for extraction. The supernatant was then collected by centrifugation. The temperature of the supernatant was lowered to -80°C and frozen, and freeze-dried for 48 hours to obtain a gray powdery dry extract 1. Next, this dried extract was dissolved in α-MEM medium (Sigma) to a concentration of 25 mg / mL, and filter-sterilized to obtain Sample 1. The filter used was a Minisart 0.22 μm filter manufactured by Sartorius.

[0038] Next, mouse macrophage-like cell line RAW264 cells (obtained from the American Type Culture Collection's US Bioresource Bank) were used as osteoclast precursor cells, and were pre-cultured for 2 days in α-MEM medium (Sigma) supplemented with 10% fetal bovine serum (FBS) at 37°C and 100% humidity, and then cultured for 5 days in 10% FBS-α-MEM medium supplemented with RANKL (Receptor activator of nuclear factor-kappa B ligand: Fujifilm Wako) at 37°C and 100% humidity to induce differentiation into osteoclasts. This was designated sample 2.

[0039] Next, the number of viable cells was measured, and cytotoxicity was measured using WST-8 (Nacalai Tesque) as a colorimetric assay kit for studying the induction or inhibition of cell proliferation. When mouse macrophage-like cell line RAW264 cells are stimulated with RANKL as a differentiation inducer and induced to differentiate into osteoclasts, they highly express tartrate-resistant acid phosphatase (TRAP), an osteoclast marker enzyme. Taking advantage of this property, we measured the inhibitory effect of osteoclast differentiation using TRAP expression as an index.

[0040] 50 μL of sample 1 was added to each well of a 96-well culture plate (Becton Dickinson). 50 μL of α-MEM medium was added to the blank and control. Then, 1.4 × 10 cells of sample 2 were cultured in 20% FBS-α-MEM medium. 4 The final concentration of RANKL was adjusted to 150 cells / mL and added at 50 μL to the blank wells. RANKL was added to the remaining cell suspension of sample 2 to a final concentration of 150 ng / mL, mixed well, and then 50 μL was seeded into the remaining wells. After culturing for 5 days, the medium in the 96-well plate was removed, and 50 μL of TRAP staining reagent was added to each well and incubated at 37°C for 4 hours.

[0041] After 4 hours, the supernatant was removed and the plate was washed with 100 μL of distilled water. 200 μL of distilled water was added to each well to terminate the staining, and the cells were observed and photographed. Then, 100 μL of DMSO (Sigma) was added to each well, and the plate was shaken for 15 minutes to elute the dye. After 15 minutes, the absorbance at 540 nm was measured using an iMARK microplate reader (Bio-Rad).

[0042] The TRAP staining reagent used in the experiment is as follows: 20 μL of 2% naphthol AS-MX phosphate solution (Sigma) and 40 μL of 6% Fast Red Violet LB salt solution (Sigma) were added to 4 mL of TRAP buffer. The same applies to the following cases.

[0043] The concentrations of Sample 1 added to the medium were adjusted to give final concentrations in the medium of 3.1 mg / mL, 1.6 mg / mL, and 0.8 mg / mL, respectively. A real-time RT-PCR experiment (Applied Biosystems, SteoOnePlus) was used for the experiment. The results are shown in Figures 1 and 2 below.

[0044] FIG. 1 is a graph showing the results of a cytotoxicity evaluation test using Sample 1. A commercially available cytotoxicity assay kit (Cell Counting Kit-8, Dojindo Laboratories) was used for the cytotoxicity evaluation test. In the graph of FIG. 1, the vertical axis indicates the relative cell viability (%), and the horizontal axis indicates the concentration of Sample 1 (mg / mL). 1, reference number 1 indicates the concentration of sample 1 added to the medium, which is 0.8 mg / mL based on the final concentration in the medium. Similarly, reference number 2 indicates 1.6 mg / mL, and reference number 3 indicates 3.1 mg / mL. Reference number 4 indicates the case where sample 1 was not added to the medium for comparison. As shown in FIG. 1, it was confirmed that Sample 1 exhibited no toxicity at concentrations of 3.1 mg / mL or less.

[0045] FIG. 2 is a graph showing the inhibitory effect on osteoclast differentiation, using the expression of tartrate-resistant acid phosphatase (TRAP), an osteoclast marker enzyme, as an indicator. In the graph of FIG. 2, the vertical axis indicates the relative differentiation rate (%) of osteoclast precursor cells, and the horizontal axis indicates the concentration of Sample 1 (mg / mL). Reference symbols 1 to 4 in Fig. 2 are the same as those in Fig. 1. Reference symbol 5 in Fig. 2 indicates the case of RAW264 cells before differentiation induction when Sample 1 was not used for comparison. As shown in FIG. 2, it was confirmed that Sample 1 significantly inhibited differentiation.

[0046] [Preliminary experiment 2] In the case of the above preliminary experiment 1, for the extraction process using liquid water and commercially available dried sardine powder, the water temperature was set to 100°C, which is boiling at normal pressure, and the extraction operation was carried out for 10 minutes after the temperature reached 100°C. The results are shown in Figure 3.

[0047] Figure 3 is a graph showing the inhibitory effect of osteoclast differentiation, measured by the expression of tartrate-resistant acid phosphatase (TRAP), an osteoclast marker enzyme, when dried sardine powder is extracted with boiled water (100°C) and cold water (8°C). Reference number 6 in FIG. 3 indicates the case where dried powder of boiled fish was extracted with cold water and the concentration of sample 1 added to the medium was 0.8 mg / mL as the final concentration in the medium. Reference number 7 in FIG. 3 indicates the case where dried powder of boiled dried fish was extracted with cold water and the concentration of sample 1 added to the medium was 1.6 mg / mL as the final concentration in the medium. Reference numeral 8 in FIG. 3 indicates the case where dried powder of boiled sardines was extracted with boiled water and the concentration of Sample 1 added to the medium was 0.8 mg / mL as the final concentration in the medium. Reference numeral 9 in FIG. 3 indicates the case where dried powder of boiled sardines was extracted with boiled water, and the concentration of sample 1 added to the medium was 1.6 mg / mL as the final concentration in the medium. Reference numeral 10 in FIG. 3 indicates the case where Sample 1 was not added. Reference numeral 11 in FIG. 3 indicates the case of RAW264 cells before differentiation induction when Sample 1 was not used for comparison.

[0048] Figure 4 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells before differentiation induction, and Figure 5 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells after stimulation with RANKL as a differentiation inducer for 5 days. As differentiation progresses, darker areas appear in the micrograph.

[0049] Figures 4 and 5 are for comparative reference purposes and no ingredients derived from dried sardines have been added. Figure 6 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells after stimulation with RANKL as a differentiation inducer for five days after extracting dried sardine powder with water at 8°C in accordance with preliminary experiment 1. Figure 7 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells after extraction with dried sardine powder in boiling water at 100°C for 10 minutes and then stimulation with RANKL as a differentiation inducer for 5 days, in accordance with preliminary experiment 2. As is clear from Figures 6 and 7, the active substances contained in the dried powder of Niboshi were shown to be stable to heat. EXAMPLES

[0050] 2.0 g of dried sardine powder (Marutomo) was suspended in distilled water to a concentration of 0.1 g / mL, and extracted by stirring at 8° C. for 24 hours. The extract was centrifuged at 20,000 rpm and 4° C. for 10 minutes, and the supernatant was collected. The resulting supernatant was encapsulated in a dialysis membrane (Fujifilm Wako Co., Ltd.) with a molecular weight cutoff of 14 kDa, and immersed in 5 L of distilled water at 4° C. for 20 hours to remove low molecular weight components. The dialysate was then cooled to −80° C. and frozen, and freeze-dried for 48 hours to obtain a dry extract 2 in the form of a gray powder.

[0051] Next, this dried extract 2 was dissolved in α-MEM medium (manufactured by Sigma) to a concentration of 25 mg / mL, and filter-sterilized to obtain Sample 3. The filter used was a Minisart 0.22 μm filter manufactured by Sartorius.

[0052] When mouse macrophage-like cell line RAW264 cells are stimulated with RANKL as a differentiation inducer and induced to differentiate into osteoclasts, they highly express tartrate-resistant acid phosphatase (TRAP), an osteoclast marker enzyme. Taking advantage of this property, we measured the inhibitory effect of osteoclast differentiation using TRAP expression as an index.

[0053] 50 μL of sample 3 was added to each well of a 96-well culture plate (Becton Dickinson). 50 μL of α-MEM medium was added to the blank and control. Then, the cells were cultured at a density of 1.4 × 10 4 The mixture was adjusted to 150 cells / mL and added to the blank wells at 50 μL each. RANKL was added to the remaining cell suspension to a final concentration of 150 ng / mL, mixed well, and then 50 μL each was seeded into the remaining wells. After culturing for 5 days, the medium in the 96-well plate was removed, and 50 μL each of TRAP staining reagent was added to each well and incubated at 37°C for 4 hours. The supernatant was then removed and washed with 100 μL of distilled water. Staining was terminated by adding 200 μL each of distilled water to each well, and the cells were observed and photographed. Then, 100 μL of DMSO (Sigma) was added to each well and shaken for 15 minutes to elute the dye. After 15 minutes, the absorbance at 540 nm was measured using an iMARK microplate reader (Bio-Rad). The concentrations of Sample 3 added to the medium were adjusted to give final concentrations in the medium of 1.6 mg / mL and 0.8 mg / mL.

[0054] FIG. 8 is a graph showing the inhibitory effect on osteoclast differentiation, indicated by the expression of tartrate-resistant acid phosphatase (TRAP), an osteoclast marker enzyme, when a dialysis membrane with a molecular weight cutoff of 14 kDa was used. Reference numeral 12 in FIG. 8 indicates the case where dialysis was performed and the concentration of sample 3 added to the medium was 0.8 mg / mL in terms of final concentration in the medium. Reference numeral 13 in FIG. 8 indicates the case where dialysis was performed and the concentration of sample 3 added to the medium was 1.6 mg / mL in terms of final concentration in the medium. Reference numeral 14 in FIG. 8 indicates the case where dialysis was not performed and the concentration of sample 3 added to the medium was 0.8 mg / mL in terms of final concentration in the medium. Reference numeral 15 in FIG. 8 indicates the case where dialysis was not performed and the concentration of sample 3 added to the medium was 1.6 mg / mL in terms of final concentration in the medium. Reference numeral 16 in FIG. 8 indicates the case where Sample 3 was not added. Reference numeral 17 in FIG. 8 indicates the case of RAW264 cells before differentiation induction when Sample 3 was not used for comparison.

[0055] Fig. 9 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells before differentiation induction, and Fig. 10 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells after stimulation with RANKL as a differentiation inducer for 5 days. Figures 9 and 10 are for comparative reference purposes and no ingredients derived from dried sardines have been added. FIG. 11 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells after stimulation with RANKL as a differentiation inducer for 5 days in the case of Example 1, without dialysis. FIG. 12 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells after dialysis was performed in the case of Example 1 and stimulation with RANKL as a differentiation inducer for 5 days. In Figures 11 and 12, dry extract 2 was used in a final concentration of 1.6 mg / mL in the medium.

[0056] As shown in Figure 8, when a dialysis membrane with a molecular weight cutoff of 14 kDa was used and dry extract 2, which does not pass through the 14 kDa molecular weight cutoff, was used, it was confirmed that osteoclast differentiation was inhibited when the aqueous solution of dry extract 2 was in the range of 1 mg / mL or more. The concentration of the aqueous solution of the dry extract 2 is preferably in the range of 1.0 to 3.0 mg / mL. EXAMPLES

[0057] 2.0 g of dried powder of boiled dried fish was suspended in distilled water to a concentration of 0.1 g / mL, and extracted by stirring at 8° C. for 24 hours. The extract was centrifuged at 20,000 rpm and 4° C. for 10 minutes, and the supernatant was collected. The obtained supernatant was ultrafiltered at room temperature for 5 hours using an ultrafiltration membrane with a cutoff molecular weight of 10 kDa (manufactured by Merck Millipore) to remove high molecular weight components.

[0058] The dialysate was then cooled to -80°C and frozen, and freeze-dried for 48 hours to obtain a dry extract 3 in the form of a grey powder.

[0059] Next, this dried extract 3 was dissolved in α-MEM medium (manufactured by Sigma) to a concentration of 25 mg / mL, and filter-sterilized to obtain Sample 4. The filter used was a Minisart 0.22 μm filter manufactured by Sartorius.

[0060] When mouse macrophage-like cell line RAW264 cells are stimulated with RANKL as a differentiation inducer and induced to differentiate into osteoclasts, they highly express tartrate-resistant acid phosphatase (TRAP), an osteoclast marker enzyme. Taking advantage of this property, we measured the inhibitory effect of osteoclast differentiation using TRAP expression as an index.

[0061] 50 μL of sample 4 was added to each well of a 96-well culture plate (Becton Dickinson). 50 μL of α-MEM medium was added to the blank and control. Then, the cells were cultured at 1.4 × 10 4The mixture was adjusted to 150 cells / mL and added to the blank wells at 50 μL each. RANKL was added to the remaining cell suspension to a final concentration of 150 ng / mL, mixed well, and then seeded in the remaining wells at 50 μL each. After culturing for 5 days, the medium in the 96-well plate was removed, and 50 L of TRAP staining reagent was added to each well and incubated at 37°C for 4 hours. The supernatant was then removed and washed with 100 μL of distilled water. Staining was completed by adding 200 μL of distilled water to each well, and the cells were observed and photographed. Then, 100 μL of DMSO (Sigma) was added to each well and shaken for 15 minutes to elute the dye. After 15 minutes, the absorbance at 540 nm was measured using an iMARK microplate reader (Bio-Rad). The concentrations of Sample 4 added to the medium were adjusted to give final concentrations in the medium of 1.6 mg / mL and 0.8 mg / mL.

[0062] FIG. 13 is a graph showing the inhibitory effect on osteoclast differentiation, measured using the expression of tartrate-resistant acid phosphatase (TRAP), an osteoclast marker enzyme, when an ultrafiltration membrane with an average molecular weight cutoff of 10 kDa was used. Reference numeral 18 in FIG. 13 denotes a component that does not pass through the ultrafiltration membrane when ultrafiltration is performed, and indicates the case where the concentration of sample 4 added to the medium is 0.8 mg / mL as the final concentration in the medium. Reference numeral 19 in FIG. 13 denotes a component that does not pass through the ultrafiltration membrane when ultrafiltration is performed, and indicates the case where the concentration of sample 4 added to the medium is 1.6 mg / mL as the final concentration in the medium. Reference numeral 20 in FIG. 13 indicates the case where ultrafiltration was not performed and the concentration of sample 4 added to the medium was 0.8 mg / mL in terms of final concentration in the medium. Reference numeral 21 in FIG. 13 indicates the case where ultrafiltration was not performed and the concentration of sample 4 added to the medium was 1.6 mg / mL in terms of final concentration in the medium. Reference numeral 22 in FIG. 13 indicates the case where sample 4 passed through the ultrafiltration membrane when ultrafiltration was performed, and the concentration of sample 4 added to the medium was 0.8 mg / mL in terms of final concentration in the medium. Reference numeral 23 in FIG. 13 indicates the case where sample 4 passed through the ultrafiltration membrane when ultrafiltration was performed, and the concentration of sample 4 added to the medium was 1.6 mg / mL in terms of final concentration in the medium. Reference numeral 24 in FIG. 13 indicates the case where Sample 4 was not added. Reference numeral 25 in FIG. 13 indicates the case of RAW264 cells before differentiation induction when Sample 4 was not used for comparison.

[0063] Fig. 14 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells before differentiation induction, and Fig. 15 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells after stimulation with RANKL as a differentiation inducer for 5 days. Both Figures 14 and 15 are for comparative reference purposes and no ingredients derived from dried sardines have been added. FIG. 16 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells after stimulation with RANKL as a differentiation inducer for 5 days in the case of Example 2, in which ultrafiltration was not performed. FIG. 17 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells after stimulation with RANKL as a differentiation inducer for 5 days using the components concentrated by ultrafiltration in Example 2. FIG. 18 is a micrograph showing the state of mouse macrophage-like cell line RAW264 cells after stimulation with RANKL as a differentiation inducer for 5 days in the fraction from which high molecular weight components had been removed by ultrafiltration in the case of Example 2. 16 to 18, the dry extract 3 was used after being adjusted to a final concentration of 1.6 mg / mL in the medium.

[0064] As shown in Figure 13, when an ultrafiltration membrane with an average molecular weight cutoff of 10 kDa was used and dried extract 3 that had passed through an average molecular weight cutoff of 10 kDa was used, it was confirmed that an aqueous solution of dried extract 3 in the range of 1 mg / mL or more inhibited osteoclast differentiation. The concentration of the aqueous solution of the dry extract 3 is preferably in the range of 1.0 to 3.0 mg / mL.

[0065] The results of Examples 1 and 2 suggest that the separation procedure shows that both high molecular weight and low molecular weight components inhibit osteoclast differentiation, suggesting that two or more factors are involved in the inhibition of osteoclast differentiation. In particular, it was revealed that the low molecular weight component has a stronger inhibitory effect on osteoclast differentiation than the high molecular weight component.

[0066] [Reference example 1] In order to clarify at what stage in the induction of osteoclast differentiation the dried sardine water extract shows its inhibitory effect on osteoclast differentiation, the dried extract 1 was prepared to a final concentration of 1.6 mg / mL in the medium and the inhibitory effect on osteoclast differentiation was evaluated depending on the timing of sample addition. The experiment was carried out in the same manner as in Example 1. FIG. 19 is a graph showing the relationship between the timing of addition and the effect of using a water extract of dried sardines. Reference symbol 26 in Figure 19 indicates day 0 after the start of differentiation induction. Reference symbol 27 in Figure 19 indicates day 1 after the start of differentiation induction. Reference symbol 28 in Figure 19 indicates day 2 after the start of differentiation induction. Reference symbol 29 in Figure 19 indicates day 3 after the start of differentiation induction. Reference symbol 30 in Figure 19 indicates day 4 after the start of differentiation induction. Furthermore, reference symbol 31 in Figure 19 indicates the case where the dried extract 1 was not used.

[0067] As shown in Figure 19, when the compound was applied simultaneously with the initiation of differentiation induction, a differentiation-inhibitory effect was observed, but it was confirmed that the compound did not inhibit osteoclast differentiation even when applied one day or more after the initiation of differentiation induction. [Industrial Applicability]

[0068] According to the present invention, a method for producing an osteoclast differentiation-inhibiting extract and a method for separating an osteoclast differentiation-inhibiting extract can be provided by safe and simple operations, which can prevent a decrease in bone density in the elderly and the like, and are therefore expected to be useful in medical and nursing care settings. [Explanation of symbols]

[0069] 1 Sample 1 (0.8mg / mL) 2 Sample 1 (1.6 mg / mL) 3. Sample 1 (3.1 mg / mL) 4,10,16,24,31 Control 5,11,17,25 Blank 6 Sample 1 (cold water, 0.8 mg / mL) 7 Sample 1 (cold water, 1.6 mg / mL) 8 Sample 1 (boiling water, 0.8 mg / mL) 9 Sample 1 (boiling water, 1.6 mg / mL) 12 Sample 3 (dried sardine extract with 14 kDa or less removed by dialysis, 0.8 mg / mL) 13 Sample 3 (dried sardine extract with 14 kDa or less removed by dialysis, 1.6 mg / mL) 14 Sample 3 (non-dialyzed dried fish extract, 0.8 mg / mL) 15 Sample 3 (non-dialyzed dried fish extract, 1.6 mg / mL) 18 Sample 4 (Ultrafiltration: components that do not pass through the ultrafiltration membrane, 0.8 mg / mL) 19 Sample 4 (Ultrafiltration: components that do not pass through the ultrafiltration membrane, 1.6 mg / mL) 20 Sample 4 (no ultrafiltration, 0.8 mg / mL) 21 Sample 4 (no ultrafiltration, 1.6 mg / mL) 22 Sample 4 (Ultrafiltration with high molecular weight removal, 0.8 mg / mL) 23 Sample 4 (Ultrafiltration with high molecular weight removal, 1.6 mg / mL) 26 0 days after starting differentiation induction 27 1 day after starting differentiation induction 28 2 days after starting differentiation induction 29 3 days after starting differentiation induction 30 4 days after starting differentiation induction

Claims

1. A step of extracting dried sardines with liquid water, and a step of separating components contained in the extracted water using a separation membrane; A method for producing an osteoclast differentiation-inhibiting extract, comprising:

2. The method includes a step of extracting dried sardines with liquid water, a step of separating the extracted water from a suspension of the dried sardines and the liquid water, and a step of separating components contained in the extracted water using a separation membrane, The step of separating the components contained in the extracted water using a separation membrane is a dialysis step, and the separation membrane is a dialysis membrane; The method for producing an osteoclast differentiation-inhibiting extract according to claim 1, wherein the step of separating the components contained in the extracted water using a separation membrane comprises the step of removing components having a molecular weight exceeding 14 kDa from the extracted water.

3. The method includes a step of extracting dried sardines with liquid water, a step of separating the extracted water from a suspension of the dried sardines and the liquid water, and a step of separating components contained in the extracted water using a separation membrane, The step of separating components contained in the extracted water using a separation membrane is an ultrafiltration step, and the separation membrane is an ultrafiltration membrane; The method for producing an osteoclast differentiation-inhibiting extract according to claim 1, wherein the step of separating components contained in the extracted water using a separation membrane comprises a step of removing components having a molecular weight exceeding 10 kDa from the extracted water.

4. A step of extracting dried sardines with liquid water, and a step of separating components contained in the extracted water using a separation membrane; A method for isolating an extract that inhibits osteoclast differentiation, comprising:

5. The method includes a step of extracting dried sardines with liquid water, a step of separating the extracted water from a suspension of the dried sardines and the liquid water, and a step of separating components contained in the extracted water using a separation membrane, The step of separating the components contained in the extracted water using a separation membrane is a dialysis step, and the separation membrane is a dialysis membrane; The method for separating an osteoclast differentiation-inhibiting extract according to claim 4, wherein the step of separating components contained in the extracted water using a separation membrane includes a step of removing components having a molecular weight exceeding 14 kDa from the extracted water.

6. The method includes a step of extracting dried sardines with liquid water, a step of separating the extracted water from a suspension of the dried sardines and the liquid water, and a step of separating components contained in the extracted water using a separation membrane, The step of separating components contained in the extracted water using a separation membrane is an ultrafiltration step, and the separation membrane is an ultrafiltration membrane; The method for separating an osteoclast differentiation-inhibiting extract according to claim 4, wherein the step of separating components contained in the extracted water using a separation membrane includes a step of removing components having a molecular weight exceeding 10 kDa from the extracted water.

Citation Information

Patent Citations

  • Composition for bone-strengthening acceleration

    JP2016117752A